Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Cancer Prev Res (Phila). 2012 Feb 16;5(4):612–620. doi: 10.1158/1940-6207.CAPR-11-0548

Figure 6. MK2206 and API-2 do not reduce c-FLIP levels (A and B) and only minimally enhance TRAIL-mediated cell-killing (C and D).

Figure 6

A and B, The indicated cell lines were treated with different concentrations of MK2206 or API-2 as indicated for 24 h and then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis for the given proteins. C and D, The indicated cell lines were seeded in 96-well cell culture plates and treated the next day with the given concentrations of MK2206 or API-2 alone, TRAIL alone, or TRAIL plus MK2206 or API-2. After 24 h, cell numbers were estimated using the SRB assay. Data are the means of four replicate determinations. Bars, ± SDs.